CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ('CERo' or the 'Company'), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms ...

UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline ...

Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1 Further upgraded FY 2026 financial guidance: total sales growth around ...

Disc Medicine said Monday its experimental therapy, bitopertin, met all primary and secondary endpoints in the phase 3 trial in patients with erythropoietic protoporphyria , including ...

New Recommendations for JAK Inhibitors, Anemia and Transplantation / American Society of Hematology (ASH), ASH 2026 ...

The American Society of Hematology (ASH) released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. ASH's new ...

The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or ...

Syndax Pharmaceuticals (NASDAQ:SNDX) shares fell 15% after-hours Monday following the company’s announcement that its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for ...

—With the help of routine blood tests focused on white blood cell and platelet levels, an international team of researchers set out to create a clinically applicable model to distinguish prefibrotic ...